Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29153
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTahir, Hasan-
dc.contributor.authorMease, Philip J.-
dc.contributor.authorKavanaugh, Arthur-
dc.contributor.authorReimold, Andreas-
dc.contributor.authorRech, Juergen-
dc.contributor.authorHall, Stephen-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorPellet, Pascale-
dc.contributor.authorDelicha, Eumorphia Maria-
dc.contributor.authorPricop, Luminita-
dc.contributor.authorMpofu, Shephard-
dc.date.accessioned2019-09-12T09:48:24Z-
dc.date.available2019-09-12T09:48:24Z-
dc.date.issued2019-
dc.identifier.citationRHEUMATOLOGY, 58(S3), p. 151-151-
dc.identifier.issn1462-0324-
dc.identifier.urihttp://hdl.handle.net/1942/29153-
dc.language.isoen-
dc.publisherOXFORD UNIV PRESS-
dc.titleSECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5-YEAR EFFICACY AND SAFETY RESULTS FROM THE FUTURE 1 PHASE 3 TRIAL-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateAPR 30-MAY 02, 2019-
local.bibliographicCitation.conferencenameAnnual Conference of the British-Soceity-for-Rheumatology-
local.bibliographicCitation.conferenceplaceBirmingham, ENGLAND-
dc.identifier.epage151-
dc.identifier.issueS3-
dc.identifier.spage151-
dc.identifier.volume58-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Tahir, Hasan] Barts Hlth NHS Trust, Rheumatol, London, England. [Mease, Philip J.] Swedish Med Ctr, Dermatol, Seattle, WA USA. [Mease, Philip J.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, Arthur] Univ Calif La Jolla, San Diego Sch Med, La Jolla, CA USA. [Reimold, Andreas] Dallas Vet Affairs Med Ctr, Dallas, TX USA. [Reimold, Andreas] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Rech, Juergen] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol, Erlangen, Germany. [Hall, Stephen] Emeritus Res, Rheumatol, Camberwell, Australia. [Geusens, Piet] Univ Hasselt, Rheumatol, Hasselt, Belgium. [Pellet, Pascale; Mpofu, Shephard] Novartis Pharma AG, Immunol & Dermatol, Basel, Switzerland. [Delicha, Eumorphia Maria] Novartis Pharma AG, Biostat, Basel, Switzerland. [Pricop, Luminita] Novartis Pharmaceut, Immunol Hepatol & Dermatol Franchise, E Hanover, NJ USA.-
local.publisher.placeOXFORD-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000478086100203-
item.fulltextNo Fulltext-
item.fullcitationTahir, Hasan; Mease, Philip J.; Kavanaugh, Arthur; Reimold, Andreas; Rech, Juergen; Hall, Stephen; GEUSENS, Piet; Pellet, Pascale; Delicha, Eumorphia Maria; Pricop, Luminita & Mpofu, Shephard (2019) SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5-YEAR EFFICACY AND SAFETY RESULTS FROM THE FUTURE 1 PHASE 3 TRIAL. In: RHEUMATOLOGY, 58(S3), p. 151-151.-
item.accessRightsClosed Access-
item.contributorTahir, Hasan-
item.contributorMease, Philip J.-
item.contributorKavanaugh, Arthur-
item.contributorReimold, Andreas-
item.contributorRech, Juergen-
item.contributorHall, Stephen-
item.contributorGEUSENS, Piet-
item.contributorPellet, Pascale-
item.contributorDelicha, Eumorphia Maria-
item.contributorPricop, Luminita-
item.contributorMpofu, Shephard-
crisitem.journal.issn1462-0324-
crisitem.journal.eissn1462-0332-
Appears in Collections:Research publications
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on May 10, 2024

Page view(s)

72
checked on Jul 28, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.